David Berz, M.D.
David Berz is a triple board-certified physician-scientist with expertise in Internal Medicine, Hematology and Oncology. He has extensive experience in drug development and is the holder of multiple patents. He has functioned as principal investigator in multiple clinical Phase I, II and III trials. Dr. Berz has led the basic and translational research efforts for Valkyrie Pharmaceutics, which yielded the discovery of the current lead compounds.
Born and raised in Germany, Dr. Berz earned his B.S. in Chemistry from Johann Wolfgang von Goethe Universitaet, Frankfurt and his M.D./Ph.D. from the Humboldt University, Berlin. He completed his internship and residency in Internal Medicine at Yale-affiliated Norwalk Hospital in Connecticut and his fellowship in Hematology and Oncology at Brown University.
He is a member of the International Association for the Study of Lung Cancer, Melanoma Research Society, the American Society of Clinical Oncology and the American Society of Hematology. His areas of specialty include lung malignancies, melanoma, cancer immune therapy, and personalized oncology therapeutics, and he serves as a frequent speaker and international thought leader in these areas.
Dr. Berz has key oncology publications in major journals across the United States and Europe and continues to lead multiple research efforts and investigational trials. He continues to function as the key thought leader and consultant for multiple pharmaceutical industry partners. He has numerous peer-reviewed publications in journals including The American Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Journal of Experimental Hematology and Oncology, among others.
Specialization:
Medical Oncology, Clinical Trials, and Cancer Research
